Representation of Mapi-Pharma Ltd. in a financing round
Our firm represented Mapi-Pharma Ltd. a late stage clinical biopharmaceutical company for the treatment of relapsing-remitting multiple sclerosis in a financing round of $20 million from Mylan Holdings Ltd. in support of the company’s continued Phase 3 clinical study. For more info click here.